Coronary Microvascular Dysfunction in Men with Prostate Cancer Receiving Androgen-Deprivation Therapy

​Cardiovascular disease (CVD) is a leading cause of death among men with prostate cancer. A recent study titled "Coronary Microvascular Dysfunction in Men with Prostate Cancer Receiving Androgen-Deprivation Therapy" investigates the impact of androgen-deprivation therapy (ADT) on coronary microvascular function. The research highlights that low myocardial blood flow reserve (MBFR) is strongly predictive of adverse cardiovascular outcomes in patients, regardless of the presence of coronary artery disease (CAD) and independent of traditional cardiovascular risk factors. The findings underscore the importance of monitoring coronary microvascular function in prostate cancer patients undergoing ADT to mitigate potential cardiovascular risks.​